Yalçın, N.; Akman, E.D.; Karcıoğlu, O.; Allegaert, K.; Demirkan, K.; Damadoğlu, E.; Kalyoncu, A.F. Effect of Modulator Therapies on Nutritional Risk Index in Adults with Cystic Fibrosis: A Prospective Cohort Study. Nutrients2024, 16, 1811.
Yalçın, N.; Akman, E.D.; Karcıoğlu, O.; Allegaert, K.; Demirkan, K.; Damadoğlu, E.; Kalyoncu, A.F. Effect of Modulator Therapies on Nutritional Risk Index in Adults with Cystic Fibrosis: A Prospective Cohort Study. Nutrients 2024, 16, 1811.
Yalçın, N.; Akman, E.D.; Karcıoğlu, O.; Allegaert, K.; Demirkan, K.; Damadoğlu, E.; Kalyoncu, A.F. Effect of Modulator Therapies on Nutritional Risk Index in Adults with Cystic Fibrosis: A Prospective Cohort Study. Nutrients2024, 16, 1811.
Yalçın, N.; Akman, E.D.; Karcıoğlu, O.; Allegaert, K.; Demirkan, K.; Damadoğlu, E.; Kalyoncu, A.F. Effect of Modulator Therapies on Nutritional Risk Index in Adults with Cystic Fibrosis: A Prospective Cohort Study. Nutrients 2024, 16, 1811.
Abstract
Background: Modulator therapies improve weight and body mass index (BMI) in cystic fibrosis (CF) patients. We aimed to compare the nutritional risk index (NRI) in adult CF patients receiving modulator (MT) or only non-modulator (conventional) therapies (non-MT).
Methods: A single-center prospective cohort study was conducted between June-December 2023. The NRI based on weight gain and albumin was calculated at beginning and end of a 12 weeks period in both groups. This design was pragmatic, since based on individual patient access to MT for 12 weeks.
Results: 107 patients were included [mean (SD) age: 23.85 (4.98) years, 54.7% male, 46.7% MT]. In the MT group, mean (SD) weight (kg) and albumin (g/dL) increased significantly [changes: +3.09 (2.74) and +0.17 (0.37); p
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.